The general concept of this review manuscript was presented at the 6th Nordic Pharmacoepidemiologic Network (NorPEN) meeting, Karolinska Institutet, Stockholm, Sweden, October 26, 2012.
Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs
Version of Record online: 13 FEB 2014
© 2014 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 275, Issue 6, pages 570–580, June 2014
How to Cite
UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA). Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. (Review). J Intern Med 2014; 275: 570–580., , , (
- Issue online: 27 MAY 2014
- Version of Record online: 13 FEB 2014
- National Institute on Aging at the National Institutes of Health. Grant Number: R01 AG023178
- comparative effectiveness research;
- epidemiologic methods;
- propensity scores
Treatment effects, especially when comparing two or more therapeutic alternatives as in comparative effectiveness research, are likely to be heterogeneous across age, gender, co-morbidities and co-medications. Propensity scores (PSs), an alternative to multivariable outcome models to control for measured confounding, have specific advantages in the presence of heterogeneous treatment effects. Implementing PSs using matching or weighting allows us to estimate different overall treatment effects in differently defined populations. Heterogeneous treatment effects can also be due to unmeasured confounding concentrated in those treated contrary to prediction. Sensitivity analyses based on PSs can help to assess such unmeasured confounding. PSs should be considered a primary or secondary analytic strategy in nonexperimental medical research, including pharmacoepidemiology and nonexperimental comparative effectiveness research.